PURPOSE: Lestaurtinib (CEP-701), a multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases, has undergone early phase clinical evaluation in children with relapsed neuroblastoma. We studied the interaction of CEP-701 with isotretinoin (13cRA) and fenretinide (4HPR), two retinoids that have been studied in children with high-risk neuroblastoma. METHODS: In vitro growth inhibition was assessed following a 72-hour drug exposure using the sulforhodamine B (SRB) assay in eight neuroblastoma cell lines with variable TrkB expression. When appropriate, the combination index (CI) of Chou-Talalay was used to characterize the interaction of 13cRA (non-constant ratio) or 4HPR (constant ratio) with CEP-701. RESULTS: The median (range) IC(50) of single-agent CEP-701 across all cell lines was 0.09 (0.08-0.3) μM. The combination of 13cRA and CEP-701 resulted in additive to synergistic interactions in four of the five cell lines studied. Addition of 1 or 5 μM of 13cRA decreased the median (range) CEP-701 IC(50) 1.5-fold (1.1-2.8-fold) and 1.7-fold (1.5-1.8-fold), respectively. With 10 μM 13cRA, less than 50% of cells survived when combined with various concentrations of CEP-701. The combination of 4HPR and CEP-701 trended toward being antagonistic, with a median (range) CI at the ED(50) of 1.3 (1.1-1.5). CONCLUSIONS: The combination of 13cRA and CEP-701 was additive or synergistic in a spectrum of neuroblastoma cell lines, suggesting that these agents can be potentially studied together in the setting of minimal residual disease following intensive chemoradiotherapy for children with high-risk neuroblastoma.
PURPOSE:Lestaurtinib (CEP-701), a multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases, has undergone early phase clinical evaluation in children with relapsed neuroblastoma. We studied the interaction of CEP-701 with isotretinoin (13cRA) and fenretinide (4HPR), two retinoids that have been studied in children with high-risk neuroblastoma. METHODS: In vitro growth inhibition was assessed following a 72-hour drug exposure using the sulforhodamine B (SRB) assay in eight neuroblastoma cell lines with variable TrkB expression. When appropriate, the combination index (CI) of Chou-Talalay was used to characterize the interaction of 13cRA (non-constant ratio) or 4HPR (constant ratio) with CEP-701. RESULTS: The median (range) IC(50) of single-agent CEP-701 across all cell lines was 0.09 (0.08-0.3) μM. The combination of 13cRA and CEP-701 resulted in additive to synergistic interactions in four of the five cell lines studied. Addition of 1 or 5 μM of 13cRA decreased the median (range) CEP-701 IC(50) 1.5-fold (1.1-2.8-fold) and 1.7-fold (1.5-1.8-fold), respectively. With 10 μM 13cRA, less than 50% of cells survived when combined with various concentrations of CEP-701. The combination of 4HPR and CEP-701 trended toward being antagonistic, with a median (range) CI at the ED(50) of 1.3 (1.1-1.5). CONCLUSIONS: The combination of 13cRA and CEP-701 was additive or synergistic in a spectrum of neuroblastoma cell lines, suggesting that these agents can be potentially studied together in the setting of minimal residual disease following intensive chemoradiotherapy for children with high-risk neuroblastoma.
Authors: A E Evans; K D Kisselbach; D J Yamashiro; N Ikegaki; A M Camoratto; C A Dionne; G M Brodeur Journal: Clin Cancer Res Date: 1999-11 Impact factor: 12.531
Authors: Ruth Ho; Angelika Eggert; Tomoro Hishiki; Jane E Minturn; Naohiko Ikegaki; Patricia Foster; Anna Marie Camoratto; Audrey E Evans; Garrett M Brodeur Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: Radhika Iyer; Audrey E Evans; Xiaoxue Qi; Ruth Ho; Jane E Minturn; Huaqing Zhao; Naomi Balamuth; John M Maris; Garrett M Brodeur Journal: Clin Cancer Res Date: 2010-02-23 Impact factor: 12.531
Authors: A T Weeraratna; S L Dalrymple; J C Lamb; S R Denmeade; S Miknyoczki; C A Dionne; J T Isaacs Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531
Authors: Mark Levis; Jeffrey Allebach; Kam-Fai Tse; Rui Zheng; Brenda R Baldwin; B Douglas Smith; Susan Jones-Bolin; Bruce Ruggeri; Craig Dionne; Donald Small Journal: Blood Date: 2002-06-01 Impact factor: 22.113
Authors: Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Emily Chan; Daniel Mulkerin; Mace Rothenberg; Kyle D Holen; A Craig Lockhart; James Thomas; Jordan Berlin Journal: Invest New Drugs Date: 2008-01-24 Impact factor: 3.850
Authors: Franca Formelli; Elena Cavadini; Roberto Luksch; Alberto Garaventa; Maria Grazia Villani; Valentina Appierto; Stefano Persiani Journal: Cancer Chemother Pharmacol Date: 2007-12-08 Impact factor: 3.333
Authors: Patrick P Zarrinkar; Ruwanthi N Gunawardane; Merryl D Cramer; Michael F Gardner; Daniel Brigham; Barbara Belli; Mazen W Karaman; Keith W Pratz; Gabriel Pallares; Qi Chao; Kelly G Sprankle; Hitesh K Patel; Mark Levis; Robert C Armstrong; Joyce James; Shripad S Bhagwat Journal: Blood Date: 2009-08-04 Impact factor: 22.113
Authors: Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur Journal: Cancer Chemother Pharmacol Date: 2012-05-24 Impact factor: 3.333
Authors: Filomena S G Silva; Mariana P C Ribeiro; Maria S Santos; Petronila Rocha-Pereira; Alice Santos-Silva; José B A Custódio Journal: J Bioenerg Biomembr Date: 2013-06-19 Impact factor: 2.945
Authors: Petra Werner; Prasuna Paluru; Anisha M Simpson; Brande Latney; Radhika Iyer; Garrett M Brodeur; Elizabeth Goldmuntz Journal: Hum Mutat Date: 2014-11-07 Impact factor: 4.878